Axcelead Drug Discovery Partners, Inc.

What Axcelead Drug Discovery Partners, Inc. does

Axcelead Drug Discovery Partners, Inc. is a Japan-based contract research organization that provides fully integrated drug discovery services to biotechnology and pharmaceutical companies, from target identification and validation through lead generation, optimization, candidate selection, and IND-enabling studies. Founded in 2017 as a spin-out of Takeda Pharmaceutical Company Limited, the company inherited Takeda's compound libraries, assays, and personnel, and is now a wholly owned subsidiary of Drug Discovery Gateway Investment Limited Partnership, a private equity firm. It operates a single headquarters in Fujisawa, Kanagawa, with approximately 240 employees, and serves as Japan's first drug discovery solutions provider.

The company's core technology stack combines a 1.2+ million compound library (60% internally synthesized), a track record of 700+ high-throughput screening projects, proprietary genetically modified animal models, multi-omics platforms (single-cell RNA-seq, spatial transcriptomics, proteomics, metabolomics), and an AI-powered in-silico platform called A-CODE that integrates ligand-based and structure-based drug design with cheminformatics and machine learning. The product portfolio is organized into an integrated drug discovery workflow plus standalone technology platforms (HTS, chemistry, in vitro/in vivo pharmacology, omics, bioinformatics, genetically modified animal models) and supports four therapeutic modalities: small molecules, targeted protein degraders, RNA-targeted small molecules, oligonucleotides, and peptides. Newer productized offerings include Smart-IND (a sub-12-month IND-enabling process) and A-Booster (a data-driven acceleration solution leveraging 1,000 legacy pharma projects).

Axcelead generates revenue through professional-services, project-based contracts with biotech and pharma clients, with multi-year contract cadence and negotiated pricing. The company serves a horizontal segmentation spanning large pharmaceutical companies (including Astellas, Eli Lilly, Eisai, Daiichi Sankyo, Otsuka, Fujifilm), biotechnology firms (Chordia Therapeutics, Proteros, Acadia Pharmaceuticals), and academic institutions, with over 100 facilities reported as customers. Go-to-market is primarily enterprise field sales supported by industry conferences, webinars, and content marketing. Reported operational metrics include a 95% hit identification success rate, 88% client repeat rate, and 84% lead generation/lead optimization achievement rate. The company is privately held, with stated capital of 100 million yen, and disclosed no funding rounds or revenue figures.

Name

Axcelead Drug Discovery Partners, Inc.

Legal name

Axcelead Drug Discovery Partners, Inc.

Website

https://axcelead-us.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

Axcelead Drug Discovery Partners is a Japan-based, Takeda-spun-out contract research organization providing fully integrated drug discovery services from target identification through IND-enabling to biotech and pharma clients, leveraging a 1.2+ million compound library, AI-powered A-CODE platform, and 1,000 legacy pharma projects.

Ownership category

akta.pro rank

Product category

Contract Research / Drug Discovery Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)

akta.pro secondary industries

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

Keywords

• Drug discovery services
• Contract research organization
• Preclinical research
• Medicinal chemistry
• Pharmaceutical R&D

Headquarters

HQ city

Fujisawa

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Drug Discovery Contract Research Services: Axcelead operates as a contract research organization (CRO) providing comprehensive drug discovery services to biotechnology and pharmaceutical companies. Services span from target identification and validation through lead generation, optimization, candidate selection, and IND-enabling studies. Revenue is generated through project-based contracts for these specialized research services.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Axcelead Drug Discovery Partners is a contract research organization (CRO) providing integrated drug discovery services to pharmaceutical and biotechnology companies. Their services span from target identification through IND-enabling studies, including medicinal chemistry, in vitro/in vivo pharmacology, omics, bioinformatics, and high throughput screening. They offer proprietary technologies including the A-CODE in-silico platform, Axcelead Booster compound library, and genetically modified animal models.

Product overview

Axcelead Drug Discovery Partners offers a fully integrated drug discovery solutions platform as Japan's first drug discovery solutions provider, established in 2017 as a Takeda spin-out. The core Integrated Drug Discovery platform consolidates all essential functions from target identification through IND-enabling under one roof, supported by a proprietary compound library of 1.2+ million compounds and AI-powered systems. The product portfolio includes six sub-products covering the discovery pipeline (Target Identification/Validation, Hit Identification/Characterization, Lead Generation/Optimization, Candidate Selection, IND Enabling via Smart-IND), enhanced by the add-on Axcelead Booster module for accelerated candidate generation from legacy projects. Technology platforms span High Throughput Screening, Chemistry (including A-CODE computational platform), In Vitro/In Vivo Pharmacology, Omics (single-cell, spatial, proteomics, metabolomics), Bioinformatics, and Genetically Modified Animal Models. The company supports four therapeutic modalities: Small Molecules (including Targeted Protein Degraders and RNA-Targeted Small Molecules), Oligonucleotides, and Peptides, across four therapeutic areas: Oncology, Immunology, Neuroscience, and Cardiovascular/Metabolic Disease.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 95% hit identification success rate based on 700+ HTS project experiences
• +5 more outcomes

Named customers11 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Partnerships

Five partnerships are on record, tiered core, key and supporting.

• Lilly TuneLab (Eli Lilly and Company)coreTechnology or Integration · 18 June 2026Axcelead DDP joined Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company. Under this collaboration, Axcelead DDP contributes proprietary drug discovery data to TuneLab to improve predictive models and gains access to Lilly's AI/ML models for enhanced prediction of drug-like properties across small molecules and antibody therapeutics, including ADME, safety, and preclinical attributes. Axcelead DDP is the first contract research organization to participate in TuneLab in this way. TuneLab uses federated learning to collaboratively improve predictive models without sharing raw proprietary data.
• ProteroscoreStrategic or Co-development Partner · 16 March 2026Proteros and Axcelead DDP entered a strategic collaboration to enhance discovery capabilities. Axcelead gains access to Proteros' capabilities as part of the collaboration to strengthen the combined drug discovery offering.
• Nissan Chemical CorporationkeyOEM/ Whitelabel/ Licensing Partner · 24 February 2026Nissan Chemical and Axcelead DDP entered into a license agreement for DNA-Encoded Library (DEL) technology. This partnership provides Axcelead access to DEL capabilities for hit identification and lead discovery programs.
• Astellas PharmakeyStrategic or Co-development Partner · 11 December 2025Axcelead DDP signed an agreement with Astellas for HT-ADMET (High-Throughput Absorption, Distribution, Metabolism, Excretion, and Toxicity) studies. This expands an existing relationship where Astellas utilizes Axcelead's integrated drug discovery services.
• Sekisui MedicalsupportingStrategic or Co-development Partner · 11 September 2025Sekisui Medical co-hosted a webinar with Axcelead DDP focused on accelerating and achieving optimal IND for drug discovery projects, demonstrating an ongoing partnership for combined service offerings.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Eurofins Discovery: Discovery arm of Eurofins Scientific offering HTS, medicinal chemistry, in vitro pharmacology, ADME/DMPK, and integrated drug discovery services for pharma and biotech — directly competitive across Axcelead's core discovery platforms with broader geographic reach.
• Curia (formerly AMRI): Global CDMO and CRO offering integrated drug discovery, medicinal chemistry, and in vitro/in vivo biology services — comparable on Axcelead's core discovery offerings, with broader manufacturing/CDMO services extending into clinical and commercial stages.
• WuXi AppTec: China-headquartered global CRO/CDMO with a large WuXi Biology and WuXi Chemistry preclinical discovery business covering HTS, medicinal chemistry, in vivo pharmacology, and integrated IND-enabling — directly competitive on Axcelead's service lines at greater scale.
• Charles River Laboratories: Global, publicly-traded CRO with a major Discovery and Safety Assessment segment covering preclinical drug discovery, in vitro/in vivo pharmacology, and integrated discovery services — directly comparable to Axcelead's core offering but at significantly larger scale and broader geographic reach.

Direct peers

• Reaction Biology: US-based preclinical CRO offering HTS, medicinal chemistry, and biology services for drug discovery — comparable in scale and integrated preclinical focus to Axcelead, with overlapping offerings in screening and lead optimization.
• Evotec: Publicly-traded, Germany-based preclinical CRO offering integrated drug discovery from target ID through IND, with proprietary platforms (e.g., EVOpanHunter, EVOpanOmics) and AI-driven discovery — the closest direct functional peer to Axcelead in scope and integrated service model.
• GenScript ProBio: Asia-headquartered CRO/CDMO with preclinical discovery capabilities spanning biologics, cell therapy, and small molecule discovery — partially comparable to Axcelead on discovery service lines with additional strengths in biologics manufacturing.
• Sygnature Discovery: UK-based preclinical CRO specializing in integrated drug discovery including medicinal chemistry, in vitro/in vivo pharmacology, and DMPK for biotech and pharma — comparable mid-sized integrated discovery CRO with a similar client base of biotech and pharma partners.
• Pharmaron: China-headquartered CRO offering fully integrated drug discovery and preclinical services including medicinal chemistry, DMPK, in vitro/in vivo pharmacology, and IND-enabling — directly comparable to Axcelead on integrated discovery offerings, with a similar Asia-based cost structure.

Emerging players

• Insilico Medicine: AI-native drug discovery company combining generative AI, omics, and chemistry platforms with internal pipeline development — comparable as a peer on AI-driven discovery technology (A-CODE, A-Booster) but a more disruptive, pipeline-focused model rather than a fee-for-service CRO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCiZ-ytFxbHJWfi-PS48YX_Q/featured
• LinkedInlinkedin.com/company/axcelead-drug-discovery-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axcelead Drug Discovery Partners, Inc.